Gilead's Lung Cancer Moonshot Just Crashed Back to Earth
Gilead's Trodelvy missed both primary endpoints in a pivotal first-line lung cancer trial, sending shares tumbling roughly 10%. The failure doesn't just hurt Gilead; it raises tough questions about how far TROP-2 antibody-drug conjugates can reach beyond breast cancer.
Gilead had one job: prove that Trodelvy could break out of breast cancer and become a blockbuster across solid tumors. Lung cancer was supposed to be the big expansion. Instead, the company just watched its marquee lung cancer trial miss, its stock drop roughly 3%, and Wall Street openly question whether the whole oncology growth story still holds together.
This isn't just a bad day for Gilead. It's a reality check for an entire class of cancer drugs.
The Trial That Was Supposed to Change Everything
The study was called EVOKE-03, a phase 3 trial testing Trodelvy (sacituzumab govitecan) combined with Merck's blockbuster immunotherapy Keytruda (pembrolizumab) in patients with previously untreated metastatic non-small cell lung cancer. These were patients whose tumors expressed high levels of PD-L1, a protein that typically makes them good candidates for immunotherapy.
The combo was supposed to be a one-two punch. Trodelvy is an antibody-drug conjugate, or ADC: think of it as a guided missile that locks onto a protein called TROP-2 on cancer cells and delivers a toxic payload directly inside them. Pair that targeted cell-killing with Keytruda's ability to unleash the immune system, and you've got a compelling scientific story.
Compelling, but apparently not compelling enough.
Patients on the combination lived a median of 11.8 months without their cancer progressing, compared to 7.7 months on Keytruda alone. That looks like a win on paper, right? Not so fast. The hazard ratio landed at 0.81, with a p-value of 0.0252. In plain English: the improvement didn't clear the statistical bar the trial set for itself before it started. Close only counts in horseshoes and hand grenades, not in FDA registration trials.
To make things worse, the study's independent monitoring committee concluded that a statistically significant overall survival benefit (the other primary endpoint) was unlikely at the final analysis. Both primary endpoints missed. That's not a stumble; it's a faceplant.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why This Stings More Than a Typical Trial Miss
Trodelvy has been Gilead's oncology crown jewel, the centerpiece of a strategy to transform the company from an HIV and hepatitis powerhouse into a serious cancer player. It first won FDA approval in April 2020 for metastatic triple-negative breast cancer, and Gilead spent the next six years stacking indications like a kid collecting Pokémon cards.
The playbook was classic pharma ambition: prove the drug works in one cancer, then expand into as many tumor types as possible. Breast cancer was the foundation. Urothelial (bladder) cancer came next, though that indication was withdrawn in November 2024 after confirmatory data fell short. Then, just months ago in June 2026, Trodelvy scored a first-line approval in triple-negative breast cancer, both as a solo agent and in combination with Keytruda.
Lung cancer was supposed to be the next domino. Non-small cell lung cancer is the single biggest oncology market in the world. Cracking it would have validated Gilead's entire "indication-stacking" thesis and justified years of investment. Instead, EVOKE-03's failure leaves a gaping hole in the growth narrative.
Wall Street Isn't Sugarcoating It
Analysts didn't mince words. Jefferies noted that investor sentiment toward Gilead "remains tough" after repeated Trodelvy disappointments, arguing the pipeline setbacks are raising fundamental questions about the company's strategy. When your lead analyst uses the word "tough" to describe how investors feel about your stock, that's the polite version of something much harsher.
The roughly 3% stock drop reflects more than just one failed trial. It reflects a growing concern that Trodelvy's magic may not travel well outside breast cancer. The urothelial withdrawal was strike one. This NSCLC miss is strike two. Investors are now watching the remaining pipeline catalysts (including HR-positive/HER2-negative breast cancer and cervical cancer) with considerably more skepticism.
The Bigger Question: Can TROP-2 ADCs Work in Lung Cancer at All?
This is where the story gets interesting beyond Gilead. TROP-2, the protein Trodelvy targets, is found on many types of cancer cells, not just breast tumors. In lung cancer specifically, it's linked to tumor growth, invasion, and even resistance to checkpoint inhibitors like Keytruda. That last point is especially ironic: the very biology that made combining Trodelvy with Keytruda seem logical may also explain why it didn't work as well as hoped.
But Gilead isn't the only company chasing TROP-2 in lung cancer. Daiichi Sankyo and AstraZeneca have a competing ADC called datopotamab deruxtecan (Dato-DXd) that already received FDA accelerated approval in 2025 for EGFR-mutated locally advanced or metastatic NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy. Unlike Trodelvy, which uses a payload called SN-38, Dato-DXd uses Daiichi Sankyo's proprietary DXd payload platform (the same technology behind the wildly successful Enhertu). Early data showed an overall response rate of 35.8% in a pooled population with actionable genomic alterations, with even better numbers in EGFR-mutant disease specifically, where the pooled ORR reached approximately 43%.
Then there's sacituzumab tirumotecan (SKB264), developed by Kelun-Biotech and partnered with Merck, which is advancing through phase 3 trials and represents the most notable emerging challenger in the space.
So the question isn't whether TROP-2 ADCs belong in lung cancer. It's whether the right drug, with the right payload, in the right combination and patient population, can unlock the opportunity. Trodelvy's failure doesn't kill the TROP-2 thesis in NSCLC. It narrows it.
What Comes Next for Gilead
Gilead's oncology ambitions aren't dead, but they're wounded. The company still has its Kite cell therapy franchise in blood cancers and the Arcellx/anito-cel acquisition bolstering its hematology portfolio. And Trodelvy itself continues to expand in breast cancer, with the European Commission having granted authorization for first-line metastatic triple-negative breast cancer in Europe in late July 2026.
But the lung cancer dream? That's on life support. Management had pitched oncology as the company's "second growth pillar" alongside HIV. For that pillar to stand, Trodelvy needed to prove it could be a multi-tumor franchise drug, not a breast cancer specialist with occasional cameos.
The market is now pricing in a much narrower story. And in biotech, the distance between "platform drug" and "niche asset" is measured in billions of dollars of market cap. Gilead just learned that the hard way.
Clinical & Regulatory
4 min read
Two Shots a Year. Two Infections Out of 2,180 People.
Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 people in the PURPOSE 2 trial, crushing daily Truvada by 89%. The science is settled; now comes the hard part.
